CL2021002318A1 - Métodos de tratamiento de amiloidosis al - Google Patents

Métodos de tratamiento de amiloidosis al

Info

Publication number
CL2021002318A1
CL2021002318A1 CL2021002318A CL2021002318A CL2021002318A1 CL 2021002318 A1 CL2021002318 A1 CL 2021002318A1 CL 2021002318 A CL2021002318 A CL 2021002318A CL 2021002318 A CL2021002318 A CL 2021002318A CL 2021002318 A1 CL2021002318 A1 CL 2021002318A1
Authority
CL
Chile
Prior art keywords
methods
treating amyloidosis
amyloidosis
treating
patients
Prior art date
Application number
CL2021002318A
Other languages
English (en)
Inventor
Gene Kinney
Wagner Zago
Carol Karp
Radhika Tripuraneni
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CL2021002318A1 publication Critical patent/CL2021002318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Theoretical Computer Science (AREA)

Abstract

Formulaciones de anticuerpos y métodos útiles para el tratamiento de pacientes con amiloidosis AL.
CL2021002318A 2019-03-05 2021-09-03 Métodos de tratamiento de amiloidosis al CL2021002318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02

Publications (1)

Publication Number Publication Date
CL2021002318A1 true CL2021002318A1 (es) 2022-05-06

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002318A CL2021002318A1 (es) 2019-03-05 2021-09-03 Métodos de tratamiento de amiloidosis al

Country Status (16)

Country Link
US (2) US11692024B2 (es)
EP (1) EP3934689A1 (es)
JP (1) JP2022522889A (es)
KR (1) KR20220019656A (es)
CN (1) CN113811332A (es)
AU (1) AU2020231081A1 (es)
BR (1) BR112021017550A2 (es)
CA (1) CA3132780A1 (es)
CL (1) CL2021002318A1 (es)
FR (1) FR3111560B1 (es)
IL (1) IL286040A (es)
JO (1) JOP20210245A1 (es)
MA (1) MA55209A (es)
MX (1) MX2021010665A (es)
SG (1) SG11202109645QA (es)
WO (1) WO2020178638A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
TW202346335A (zh) * 2022-01-11 2023-12-01 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
ME03528B (me) 2005-03-23 2020-04-20 Genmab As Antitijela protiv cd38 za liječenje multiplog mijeloma
EA036059B1 (ru) 2007-12-28 2020-09-21 Протена Байосайенсиз Лимитед Способ получения антитела или его фрагмента, которое специфически связывается с агрегированным амилоидным белком
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
JP6431372B2 (ja) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
CA2956820A1 (en) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US20190169280A1 (en) 2016-06-30 2019-06-06 Prothena Biosciences Limited Compositions for treating amyloidosis
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US20200002410A1 (en) 2018-06-28 2020-01-02 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
MA54923A (fr) 2019-02-12 2021-12-22 Prothena Biosciences Ltd Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires

Also Published As

Publication number Publication date
KR20220019656A (ko) 2022-02-17
CN113811332A (zh) 2021-12-17
WO2020178638A1 (en) 2020-09-10
EP3934689A1 (en) 2022-01-12
CA3132780A1 (en) 2020-09-10
MA55209A (fr) 2022-01-12
JP2022522889A (ja) 2022-04-20
BR112021017550A2 (pt) 2021-11-09
US20230331831A1 (en) 2023-10-19
SG11202109645QA (en) 2021-10-28
US20200308260A1 (en) 2020-10-01
AU2020231081A1 (en) 2021-09-30
JOP20210245A1 (ar) 2023-01-30
FR3111560A1 (fr) 2021-12-24
MX2021010665A (es) 2021-12-10
US11692024B2 (en) 2023-07-04
FR3111560B1 (fr) 2024-03-22
IL286040A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
PH12020552229A1 (en) Il-11ra antibodies
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CU20200042A7 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
AR101740A1 (es) Terapia de combinación y composiciones
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2022000481A2 (es) Inhibidores de enzimas
ECSP20077106A (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EA202092748A1 (ru) Модуляторы экспрессии apol1
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
UY38352A (es) Inhibidores de integrina alfavbeta6
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
ZA202103975B (en) Methods of treating disease with magl inhibitors
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
BR112018074231A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia